Mepivacaine - Relmada Therapeutics

Drug Profile

Mepivacaine - Relmada Therapeutics

Alternative Names: MepiGel; REL-1021; TQ-1021

Latest Information Update: 17 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TheraQuest Biosciences
  • Developer Relmada Therapeutics
  • Class Local anaesthetics; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia; Neuropathic pain
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 12 Sep 2016 Preclinical development is ongoing in USA
  • 25 Jul 2012 TheraQuest Biosciences is now called Relmada Therapeutics
  • 24 Jun 2010 Preclinical trials in Diabetic neuropathies in USA (Topical, Cream)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top